Genmab A/S (GMAB): A Bull Case Theory [Yahoo! Finance]
Genmab A/S - American Depositary Shares (GMAB)
Company Research
Source: Yahoo! Finance
Genmab A/S (GMAB)'s share was trading at $20.20 as of March 18 th . GMAB's trailing and forward P/E were 11.41 and 11.61 respectively according to Yahoo Finance. A medical professional in a hospital, using targeted cancer therapuetics to treat cancer patients. Genmab (GMAB) is a leading biotech company based in Copenhagen, specializing in antibody-based therapies for cancer. Operating under a partnership-driven model, GMAB collaborates with major pharmaceutical firms like J&J and Pfizer, focusing on licensing its innovations in exchange for royalties and milestone payments. While this model has historically provided steady revenue, the company is gradually shifting toward co-developing and co-commercializing its own drugs, a mo
Read more
Impact Snapshot
Event Time:
GMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GMAB alerts
High impacting Genmab A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GMAB
News
- TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after ChemotherapyBusiness Wire
- Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.GlobeNewswire
- Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer [Yahoo! Finance]Yahoo! Finance
- Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian CancerBusiness Wire
- Genmab A/S (NASDAQ: GMAB) had its price target lowered by analysts at Truist Financial Co. from $50.00 to $45.00. They now have a "buy" rating on the stock.MarketBeat